RxDoctor Payments Data

Jesus Gonzalez Lugo, MD

Hematology & Oncology · Westwood, KSNPI 1306208061

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,860 of the $4,084 with a category attached, or 70.0%. Autolus Inc accounts for 77.7% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $3,668, more than ten times the $122 reported in 2022.

$4,084in general payments, 2019–2025

Across 12 payments — averaging $340.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Autolus Inc$3K
  • Amgen$255
  • Bristol Myers Squibb$214
  • Exelixis Inc.$174
  • Syndax Pharmaceuticals, Inc.$166
  • E.r. Squibb & Sons, L.L.C.$65
  • plus $39 from 1 others
$89,087in research payments, 2019–2025

Across 1 payment — averaging $89,087 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$89K

What the payments were for

  • Speaking & faculty fees$2,86070%
  • Travel & lodging$942%
  • Food & beverage$1,13028%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,084 in reported general payments places this provider in the 60th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$127,781
Medicare patients
176
Services billed
1,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate33$510,537
SprycelDasatinib31$501,607
RevlimidLenalidomide11$263,936
InqoviDecitabine/Cedazuridine16$128,092
VenclextaVenetoclax28$46,378
Posaconazole30$24,535
Acyclovir119$2,442
Levofloxacin54$1,134
Fluconazole32$1,102
Potassium Chloride26$649
Hydroxyurea18$346
Ondansetron OdtOndansetron16$244
Ondansetron Hcl26$192
Prochlorperazine Maleate11$108
Tramadol Hcl23$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sprycel$65$501,60731 claims
Bristol Myers SquibbRevlimid$214$263,93611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 97 hematology & oncology providers in Kansas.

Other hematology & oncology in Westwood

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →